New drug combo shows promise in early pancreatic cancer trial

NCT ID NCT05546853

Completed Disease control Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main goal was to check side effects, and researchers also looked at tumor response and survival. Results are preliminary and need further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP137 (a drug) combined with standard chemotherapy (mFOLFIRINOX)
What this could lead to: If successful, this combination could improve tumor shrinkage and survival for people with locally advanced pancreatic cancer.
What could go wrong: This is a very early Phase 1 trial with only 43 people, so safety and effectiveness are not yet proven. The added drug may cause more side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

AP-HP Pitié Salpetrière

Paris, 75013, France
CHRU Lille

Lille, 59037, France
CHU Poitiers

Poitiers, 86000, France
CHU Rennes

Rennes, 35033, France
CHU St Etienne

Saint-Etienne, 42055, France
CHU de BORDEAUX

Bordeaux, 33404, France
CHU de GRENOBLE ALPES

Grenoble, Alpes, 38043, France
CHU de REIMS

Reims, 51092, France
Hôpital Privé Jean Mermoz

Lyon, 69008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.